Alcobra Ltd. to Provide Corporate Overview at the JMP Securities Healthcare Conference

By GlobeNewswire,  June 17, 2014, 08:00:00 AM EDT


TEL AVIV, Israel, June 17, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder ( ADHD ) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the JMP Securities Healthcare Conference, taking place June 24-25 in New York City.

JMP Securities Healthcare Conference Presentation Details
Date: Tuesday, June 24, 2014
Time: 2:00pm Eastern
Location:  Embassy Room, Westin Grand Central Hotel, New York
Webcast: http://wsw.com/webcast/jmp24/ADHD/

About Alcobra Ltd.

Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder ( ADHD ) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder in adults, and is enrolling patients in a Phase III study. The company expects to begin separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome in 2014. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

Forward Looking Statements - This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Alcobra's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Alcobra could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding expected timing of beginning of clinical trials, if such trials would begin at all. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results referred to in this press release would be interpreted differently in light of additional research and clinical and preclinical trials results. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Alcobra Ltd.'s Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 28, 2014, and in subsequent filings with the SEC. Except as otherwise required by law, Alcobra disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: U.S. Investor Contacts
         LifeSci Advisors, LLCMichael Rice
         646-597-6979
         mrice@lifesciadvisors.com

         Media Inquiries
         Sam Brown, Inc.Mike Beyer
         773-463-4211
         mikebeyer@sambrown.com

         Israel Investor Contact:
         Alcobra Investor Relations
         Debbie Kaye
         +972-72 2204661
         debbie@alcobra-pharma.com

Source: Alcobra Ltd.

This article appears in: News Headlines

Referenced Stocks: ADHD


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
TWTR $ 46.30 7.71 ▲ 19.98%
BAC $ 15.58 0.24 ▲ 1.56%
SIRI $ 3.46 0.06 ▲ 1.76%
AMD $ 3.82 0.03 ▲ 0.79%
GNW $ 13.98 2.28 ▼ 14.02%
FB $ 74.677 0.97 ▲ 1.31%
PFE $ 29.26 0.21 ▼ 0.71%
AAPL $ 98.15 0.23 ▼ 0.23%

As of 7/30/2014, 04:04 PM